PRME
Price
$3.47
Change
-$0.09 (-2.53%)
Updated
Sep 9 closing price
Capitalization
631.19M
50 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$10.81
Change
-$0.37 (-3.31%)
Updated
Sep 9 closing price
Capitalization
1.83B
49 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PRME vs VIR

PRME vs VIR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PRME vs. VIR commentary
Sep 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and VIR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 10, 2026
Stock price -- (PRME: $3.47 vs. VIR: $10.81)
Brand notoriety: PRME and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 127% vs. VIR: 115%
Market capitalization -- PRME: $631.19M vs. VIR: $1.83B
PRME [@Biotechnology] is valued at $631.19M. VIR’s [@Biotechnology] market capitalization is $1.83B. The market cap for tickers in the [@Biotechnology] industry ranges from $132.08B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileVIR’s FA Score has 1 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, VIR is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).

  • PRME’s TA Score: 5 bullish, 4 bearish.
  • VIR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VIR is a better buy in the short-term than PRME.

Price Growth

PRME (@Biotechnology) experienced а -5.45% price change this week, while VIR (@Biotechnology) price change was -6.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.96%. For the same industry, the average monthly price growth was -1.95%, and the average quarterly price growth was +2729.16%.

Reported Earning Dates

PRME is expected to report earnings on Oct 30, 2026.

VIR is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-3.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VIR($1.83B) has a higher market cap than PRME($631M). VIR YTD gains are higher at: 79.270 vs. PRME (0.000). PRME has higher annual earnings (EBITDA): -189.12M vs. VIR (-268.68M). VIR has more cash in the bank: 533M vs. PRME (47.5M). VIR has less debt than PRME: VIR (93.3M) vs PRME (112M). VIR has higher revenues than PRME: VIR (303M) vs PRME (4.07M).
PRMEVIRPRME / VIR
Capitalization631M1.83B35%
EBITDA-189.12M-268.68M70%
Gain YTD0.00079.270-
P/E RatioN/AN/A-
Revenue4.07M303M1%
Total Cash47.5M533M9%
Total Debt112M93.3M120%
FUNDAMENTALS RATINGS
PRME vs VIR: Fundamental Ratings
PRME
VIR
OUTLOOK RATING
1..100
6790
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
4336
P/E GROWTH RATING
1..100
10023
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (34) in the null industry is in the same range as VIR (57). This means that PRME’s stock grew similarly to VIR’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as VIR (100). This means that PRME’s stock grew similarly to VIR’s over the last 12 months.

PRME's SMR Rating (95) in the null industry is in the same range as VIR (96). This means that PRME’s stock grew similarly to VIR’s over the last 12 months.

VIR's Price Growth Rating (36) in the null industry is in the same range as PRME (43). This means that VIR’s stock grew similarly to PRME’s over the last 12 months.

VIR's P/E Growth Rating (23) in the null industry is significantly better than the same rating for PRME (100). This means that VIR’s stock grew significantly faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMEVIR
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
68%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 10 days ago
73%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
71%
View a ticker or compare two or three
PRME
Daily Signal:
Gain/Loss:
VIR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PJFM66.490.26
+0.39%
PGIM Jennison Focused Mid-Cap ETF
DBA29.00-0.13
-0.45%
Invesco DB Agriculture
SSK13.82-0.10
-0.72%
REX-Osprey SOL + Staking ETF
EDOW45.34-0.36
-0.79%
First Trust Dow 30 Equal Weight ETF
RSMR24.03-0.25
-1.03%
FT Vest U.S. Equity Equal Weight Buffer ETF - March

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
-3.31%
BEAM - VIR
54%
Loosely correlated
-6.17%
DNLI - VIR
52%
Loosely correlated
-2.31%
EDIT - VIR
51%
Loosely correlated
-8.58%
RCUS - VIR
50%
Loosely correlated
-1.96%
PRME - VIR
49%
Loosely correlated
-2.53%
More